Qiliqiangxin Capsule in Patients with Chronic Heart Failure Complicated by Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Trials
DOI:
https://doi.org/10.71204/y50qbv78Keywords:
Qiliqiangxin Capsule, Chronic Heart Failure, Coronary Artery Disease, Meta-AnalysisAbstract
To explore the clinical value and potential risk of Qiliqiangxin Capsule, we designed a systematic review and meta-analysis on randomized controlled trials (RCTs), targeting patients diagnosed with both chronic heart failure and coronary artery disease. Our search included eight commonly used databases, focusing on studies that assessed the effectiveness of Qiliqiangxin Capsule and guideline-directed medical therapy for patients whose condition was chronic heart failure complicated by coronary artery disease. We conducted the meta-analysis employing the meta and metafor packages running under R 4.5.3, whereas the risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool. After systematic screening procedure, we included 17 studies, involving 2000 eligible patients. The results showed that Qiliqiangxin Capsule combination treatment reduced the occurrences of the primary outcome [RR=0.38,95%CI (0.23,0.63)], left ventricular ejection fraction (LVEF) [MD=5.39,95%CI (4.62,6.16)], left ventricular end-diastolic diameter (LVEDD) [MD=-4.86,95% CI(-6.20,-3.51)], N-terminal B-type natriuretic peptide precursor (NT-proBNP) levels [SMD = -0.82, 95% CI (-0.97, -0.67)], the 6-minute walk test distance (6MWD) [MD=39.05,95%CI(19.90,58.20)], and the clinical efficacy [RR = 1.20, 95% CI (1.14, 1.25)] were also significantly improved. As for the safety evaluation, the incidence of adverse events was not found to differ meaningfully [RR = 0.95, 95% CI (0.60, 1.50) ]. The combination of Qiliqiangxin Capsule and guideline-directed medical therapy can safely and effectively improve the heart failure rehospitalization and all-cause mortality in patients with chronic heart failure complicated by coronary artery disease, improve cardiac performance, increase physical capacity. However, further large sample trials are required to confirm the results.
References
Arata, A., Ricci, F., Khanji, M. Y., et al. (2023). Sex Differences in Heart Failure: What Do We Know? J Cardiovasc Dev Dis, 10(7), 277. DOI: https://doi.org/10.3390/jcdd10070277
Boying, Q., Yinglan, Y., and Ying, T. (2022). Effects of Qiliqiangxin Capsule and Trimetazidine on Serum NT pro BNP Level and Cardiac Function in Patients with Coronary Heart Disease and Heart Failure. Capit Food Med, 29(21).
Bozkurt, B., Ahmad, T., Alexander, K., et al. (2025). HF STATS 2024: Heart Failure Epidemiology and Outcomes Statistics An Updated 2024 Report from the Heart Failure Society of America. J Card Fail, 31(1), 66-116. DOI: https://doi.org/10.1016/j.cardfail.2024.07.001
Changqing, X., Fang, W., Na, Z., et al. (2021). Curative Efficacy of Qili Qiangxin Capsules in Treatment of Heart Failure of Elderly Patients with Coronary Heart Disease. World Chin Med, 16(18), 2751-2756.
Cheang, I., Yao, W., Zhou, Y., et al. (2024). The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial. Nat Med, 30(8), 2295-2302. DOI: https://doi.org/10.1038/s41591-024-03169-2
Chinese Society of Cardiology, Chinese Medical Association, Chinese College of Cardiovascular Physician, C. H. F. a. O. C. M. D. A., and Cardiology, E. B. O. C. J. O. (2024). Chinese guidelines for the diagnosis and treatment of heart failure 2024. Chin J Cardiol 52(03), 235-275.
Danmei, Y., and Zhengjian, L. (2017). Application value of Qili Qiangxin capsule in the treatment of coronary heart disease combined with chronic heart failure. Clin Res Pract, 2(12), 33-34.
Duval, S., and Tweedie, R. (2000). Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics, 56(2), 455-463. DOI: https://doi.org/10.1111/j.0006-341X.2000.00455.x
Fiuzat, M., Ezekowitz, J., Alemayehu, W., et al. (2020). Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol, 5(7), 757-764. DOI: https://doi.org/10.1001/jamacardio.2020.0640
Haijing, G., and Zhigang, Z. (2022). Pharmacoeconomic evaluation of Qili qiangxin capsule in the treatment of chronic heart failure. China Pharm, 33(02), 209-216.
Heusch, G. (2022). Coronary blood flow in heart failure: cause, consequence and bystander. Basic Res Cardiol, 117(1), 1. DOI: https://doi.org/10.1007/s00395-022-00909-8
Hua, W. (2017). Effect of Qiliqiangxin capsule on Serum Adiponectin Levels and Heart Function in Patients with Coronary Heart Disease and Heart Failure. Mod J Integr Tradit Chin West Med, 26(22), 2450-2452.
Jia, G., Aroor, A. R., Hill, M. A., and Sowers, J. R. (2018). Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness. Hypertension, 72(3), 537-548. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.118.11065
Jia, Y., Zuo, D., Li, Z., et al. (2014). Astragaloside IV inhibits doxorubicin-induced cardiomyocyte apoptosis mediated by mitochondrial apoptotic pathway via activating the PI3K/Akt pathway. Chem Pharm Bull (Tokyo), 62(1), 45-53. DOI: https://doi.org/10.1248/cpb.c13-00556
Jiang, H., Fang, T., and Cheng, Z. (2023). Mechanism of heart failure after myocardial infarction. J Int Med Res, 51(10), 3000605231202573. DOI: https://doi.org/10.1177/03000605231202573
Jiang, Y. (2019). Investigation of the Effects of QiliQiangxin Capsule Combined with Bisoprolol on Vascular Endothelial Function and Cardiac Performance in Patients with Coronary Heart Disease and Heart Failure. Med J Chin People's Health, 31(14), 100-102.
Jiaqi, H., Houze, T., Yaling, Z., and Shifeng, X. (2025). Clinical observation of Qiliqiangxin capsule on patients with chronic heart failure complicated with coronary heart disease. Chin Arch Tradit Chin Med, 1-11.
Jinhua, G. (2019). Clinical observation of Qiliqiangxin capsule Combined with Trimetazidine on patients with Heart Failure of Coronary Heart Disease. Mod Diagn Treat, 30(01), 36-37.
Jinyu, S., Xin, D., Jihong, S., and Yongzhi, W. (2020). Effects of Qili Qiangxin Capsule Combined with Milrinone on Arterial Hemodynamics and Heart Function in Patients with Myocardial Infarction Complicated with Heart Failure. Shaanxi J Tradit Chin Med, 41(04), 493-495.
Li, Q., Shen, L., Wang, Z., et al. (2016). Tanshinone IIA protects against myocardial ischemia reperfusion injury by activating the PI3K/Akt/mTOR signaling pathway. Biomed Pharmacother, 84, 106-114. DOI: https://doi.org/10.1016/j.biopha.2016.09.014
Libby, P. (2002). Inflammation in atherosclerosis. Nature, 420(6917), 868-874. DOI: https://doi.org/10.1038/nature01323
Mcdonagh, T. A., Metra, M., Adamo, M., et al. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J, 42(36), 3599-3726. DOI: https://doi.org/10.1093/eurheartj/ehab368
Mcdonagh, T. A., Metra, M., Adamo, M., et al. (2023). 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J, 44(37), 3627-3639. DOI: https://doi.org/10.1093/eurheartj/ehad195
Meijuan, Qi., Han, Z., Fenfen, Z., et al. (2024). Efficacy of Qili Qiangxin capsule combined with dapagliflozin in treatment of newly developing heart failure after acute myocardial infarction. Chin J Drug Appl & Monit, 21(05), 661-664.
Packer, M. (2023). Qiliqiangxin: A multifaceted holistic treatment for heart failure or a pharmacological probe for the identification of cardioprotective mechanisms? Eur J Heart Fail, 25(12), 2130-2143. DOI: https://doi.org/10.1002/ejhf.3068
Page, M. J., Mckenzie, J. E., Bossuyt, P. M., et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj, 372, n71. DOI: https://doi.org/10.1136/bmj.n71
Qin, Q., Lin, N., Huang, H., et al. (2019). Ginsenoside Rg1 ameliorates cardiac oxidative stress and inflammation in streptozotocin-induced diabetic rats. Diabetes Metab Syndr Obes, 12, 1091-1103. DOI: https://doi.org/10.2147/DMSO.S208989
Ronglai, Y. (2020). Effect of Qili Qiangxin Capsule on Serum APN，cTnI and Prognosis in Patients with Heart Failure of Coronary Heart Disease. Guangming J Chin Med, 35(17), 2711-2713.
Shige, L., Xiaodan, Z., and Zhangzheng, Y. (2024). Clinical Efficacy of Sacubitril Valsartan Combined with Qili Qiangxin Capsule in the Treatment of Coronary Heart Disease with Heart Failure. Shenzhen J Integr Tradit Chin West Med, 34(20), 33-36.
Shisheng, G., Donghua, L., and Jiwei, Z. (2020). Application of Trimetazidine Combined with Qili Qiangxin Capsule in Treatment of Heart Failure of Elderly Patients with Coronary Heart Disease. Cardiovasc Dis Electron J Integr Tradit Chin West Med, 8(17), 52-53.
Sterne, J. a. C., Savović, J., Page, M. J., et al. (2019). RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj, 366, l4898. DOI: https://doi.org/10.1136/bmj.l4898
Vrints, C., Andreotti, F., Koskinas, K. C., et al. (2024). 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J, 45(36), 3415-3537. DOI: https://doi.org/10.1093/eurheartj/ehae177
Wang, L., and Zhang, Q. (2024). Effectiveness of Qiliqiangxin Combined with Trimetazidine Hydrochloride Tablets in Treating Coronary Heart Disease with Concurrent Heart Failure: A Comparative Study. Curr Top Nutraceutical Res, 22(2), 446-451. DOI: https://doi.org/10.37290/ctnr2641-452X.22:446-451
Xiling, Z. (2020). Effect of Qiliqiangxin capsule Combined with Trimetazidine on Plasma Brain Natriuretic Peptide and Vascular Endothelial Function in Elderly Patients with Coronary Heart Disease and Heart Failure. Mod J Integr Tradit Chin West Med, 29(01), 77-80.
Xinhua, C., Qi，Sun., Liang，Li., et al. (2014). Effect of Qiliqiangxin capsules on neurohumoral factors，left ventricular remodeling and heart function in the patients with ischemic heart disease with heart failure. Mod J Integr Tradit Chin West Med, 23(25), 2760-2763.
Yahui, C., Junpeng, X., Haiyue, Z., et al. (2020). Systematic Evaluation of Efficacy and Safety Qili Qiangxin Capsules in the Treatment of Acute Myocardial Infarction Complicated with Heart Failure. Eval Anal Drug-Use Hosp China, 20(06), 698-703.
Yan, Y., Xiaofang, H., Xiaoyun, L., et al. (2021). Systematic Review on Qili Qiangxin Capsules Combined with Conventional Western Therapy in Treatment of Coronary Heart Disease with Chronic Heart Failure. Chin J Inf TCM, 28(02), 39-45.
Yan, Z., Ting, M., Yaping, B., et al. (2020). Clinical features and prognosis of patients with different types of heart failure in relation to coronary artery disease. Natl Med J China, 100(15), 1142-1147.
Yang, T., Miao, Y., Zhang, T., et al. (2018). Ginsenoside Rb1 inhibits autophagy through regulation of Rho/ROCK and PI3K/mTOR pathways in a pressure-overload heart failure rat model. J Pharm Pharmacol, 70(6), 830-838. DOI: https://doi.org/10.1111/jphp.12900
Yaoqi, C., Jinxing, M., Yanxin, L., et al. (2020). Effect of Qiliqiangxin capsule on heart function，renal function and prognosis in patients with old myocardial infarction and heart failure Chin J Diffic and Compl Cas, 19(08), 785-790.
Yuxian, C., Shujun, Y., and Juping, D. (2021). Clinical Study on Qili Qiangxin Capsules Combined with Routine Western Medicine for Ischemic Cardiomyopathy Complicated with Heart Failure. J New Chin Med, 53(15), 40-43.
Zhou, B., and Tian, R. (2018). Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Invest, 128(9), 3716-3726. DOI: https://doi.org/10.1172/JCI120849
Zhu, R., Zheng, J., Chen, L., et al. (2016). Astragaloside IV facilitates glucose transport in C2C12 myotubes through the IRS1/AKT pathway and suppresses the palmitate-induced activation of the IKK/IκBα pathway. Int J Mol Med, 37(6), 1697-1705. DOI: https://doi.org/10.3892/ijmm.2016.2555
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Kaijuan Wang, Jinhao Xu, Xiangying Zheng, Fengshuo Chang, Jingen Li (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in this journal are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are properly credited. Authors retain copyright of their work, and readers are free to copy, share, adapt, and build upon the material for any purpose, including commercial use, as long as appropriate attribution is given.
How to Cite
